AI Will Drive the Next New Wave of Innovation

Cathy Wood believes that rapprochement, especially artificial intelligence creates transformative investment opportunities across multiple sectors despite the current uncertainty in the market.

During an online symposium hosted by the investment platform in the United Kingdom on Thursday, the CEO of ARK Invest and the largest investment officials identified how artificial intelligence accelerated innovation through health care, independent leadership and software development with the main economic growth forecasts mainly during the next five years.

According to Wood, “Artificial Intelligence is the biggest catalyst for change there,” describing how artificial intelligence will affect all technology and accelerate innovation across sectors.

The investment strategy highlighted how its company analysts organize around these technologies instead of traditional sectors, allowing them to determine opportunities that extend multiple industries.

Artificial intelligence transforms the main areas such as independent driving, where Wood believes that Tesla Inc. (TSLA) will reach a decisive safe mark this year.

“By the end of this year, we believe, thanks to artificial intelligence, that robotics, or at least robotics Tesla, will be safer than a human driver,” Wood stated, noting that Tesla is approaching the safety threshold for one accident per 700,000 miles achieved by human drivers.

This improvement in safety, as well as the organizational changes that Wood expects within the framework of current management, can accelerate the adoption of independent leadership technology and the transfer of transport economics.

“The final price is widely … when expanding the range of a full global robotics network, it will be 25 cents per mile compared to $ 2 to 4 dollars per mile,” Wood explained now.

Amnesty International’s transformation on health care was the other focus, especially in drug discovery, as companies such as Recursion Therapeutics Inc. (RXRX) The researcher’s productivity is ten times more in one year, according to Wood.

“The number of hypotheses that the researcher can test in Recursion Therapeutics has moved from 20 to 200 a year,” she said, adding that the schedule for the development of medicines may shrink from 13 years to eight years while costs drop from $ 2.4 billion to 600 million dollars per medicine.

Besides market fluctuations in the short term, Wood maintains an optimistic look with a vision of rapid economic growth driven by rapprochement technologies.

For the next five years, we expect that [GDP] The rate of growth to more than twice, based on the convergence of technologies, “predicts Wood, referring to the historical precedents of technological breakthroughs that lead to an increase in economic growth.